Skip to content

Four-year analysis of tenofovir finds “favourable safety profile”

A short course of potent HIV therapy during primary infection may slow longer-term disease progression

Dutch study and Canadian editorial call for earlier intiation of ART

Abacavir hypersensitivity screen as part of drug resistance test possible

Testosterone levels, fat free mass, increases differ according to HIV drugs taken

Depression increases mortality risk in non-adherent individuals on first-line ART

Further evidence that HIV/hepatitis C coinfected patients have poorer immunological response to HIV therapy

Elimination of HIV from body within eight years if treatment starts just after infection, predict US researchers; sceptics disagree

Tool to calculate prognosis for patients starting HIV therapy updated